CHATHAM, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced it has completed the acquisition of its new research and development center (RDC) located in Frederick, Md. The approximately 48,000 square foot facility will support Tonix’s expanding infectious disease pipeline, including:
- TNX-1800 – a live virus vaccine designed to protect against COVID-19
- TNX-801 – a live virus vaccine designed to protect against smallpox and monkeypox
- TNX-3500 – a small molecule antiviral under development to treat COVID-19
- TNX-2100 – a peptide based skin test to measure functional T cell immunity to SARS-CoV-2
Tonix purchased the RDC from Southern Research, a collaborating partner on TNX-1800 and TNX-801 development.
{iframe}https://www.citybiz.co/article/152473/tonix-pharmaceuticals-announces-completion-of-acquisition-of-infectious-disease-rd-center-in-frederick-maryland/?abkw=citybizwashington{/iframe}